Baker BROS. Advisors LP Has $51.11 Million Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Baker BROS. Advisors LP lifted its holdings in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 6.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,633,838 shares of the company's stock after buying an additional 265,395 shares during the quarter. Stoke Therapeutics comprises approximately 0.5% of Baker BROS. Advisors LP's investment portfolio, making the stock its 24th biggest holding. Baker BROS. Advisors LP owned about 8.75% of Stoke Therapeutics worth $51,111,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of STOK. Freestone Grove Partners LP bought a new position in Stoke Therapeutics in the fourth quarter valued at approximately $199,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of Stoke Therapeutics in the 4th quarter valued at $3,218,000. Northern Trust Corp boosted its position in shares of Stoke Therapeutics by 3.4% in the 4th quarter. Northern Trust Corp now owns 350,788 shares of the company's stock worth $3,869,000 after purchasing an additional 11,635 shares during the last quarter. Tudor Investment Corp ET AL acquired a new stake in shares of Stoke Therapeutics during the fourth quarter worth $201,000. Finally, Gilder Gagnon Howe & Co. LLC increased its holdings in Stoke Therapeutics by 2.0% in the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 92,546 shares of the company's stock valued at $1,021,000 after purchasing an additional 1,791 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. HC Wainwright restated a "buy" rating and set a $47.00 target price on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Chardan Capital reissued a "buy" rating and set a $24.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Wednesday, April 9th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $25.60.

Stoke Therapeutics Stock Performance

STOK traded up $0.39 on Friday, hitting $9.44. 462,675 shares of the company were exchanged, compared to its average volume of 711,105. The stock's fifty day moving average is $7.99 and its 200-day moving average is $10.09. Stoke Therapeutics, Inc. has a 12 month low of $5.35 and a 12 month high of $17.58. The company has a market cap of $515.40 million, a PE ratio of -4.50 and a beta of 1.20.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.56) by $0.38. The company had revenue of $22.61 million during the quarter, compared to analysts' expectations of $4.20 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. As a group, equities research analysts expect that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Insider Activity

In other news, Director Edward M. Md Kaye sold 10,382 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the sale, the director now directly owns 148,253 shares in the company, valued at approximately $1,285,353.51. The trade was a 6.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Barry Ticho sold 3,884 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the sale, the insider now owns 63,962 shares of the company's stock, valued at approximately $554,550.54. This trade represents a 5.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 16,532 shares of company stock valued at $143,332. 11.30% of the stock is owned by insiders.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.